Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

December 2, 2022

Celebrating 35 Years of Innovation and Impact: An Interview Series

For 35 years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to...

Read article

October 24, 2022

Cyrus Mehta on the Founding of Cytel

On the occasion of Cytel’s 35th anniversary, co-founder Professor Cyrus Mehta sits down with Dr. Esha Senchaudhuri to...

Read article

October 18, 2022

Nitin Patel on 35 Years of Technological Innovation

On the occasion of Cytel’s 35th anniversary, co-founder Professor Nitin Patel sits down with Dr. Esha Senchaudhuri to...

Read article

October 11, 2022

Joshua Schultz on the Evolution of Cytel

On the occasion of Cytel’s 35th anniversary, our CEO Joshua Schultz sits down with Dr. Esha Senchaudhuri to discuss the...

Read article